<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407654</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00176</org_study_id>
    <secondary_id>PHL-050</secondary_id>
    <secondary_id>CDR0000518293</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <nct_id>NCT00407654</nct_id>
  </id_info>
  <brief_title>VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well VEGF Trap works in treating patients with previously&#xD;
      treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by&#xD;
      blocking blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate (complete and partial) in patients with previously treated&#xD;
      metastatic colorectal cancer treated with VEGF Trap.&#xD;
&#xD;
      II. Determine the incidence of disease stabilization, in terms of 4-month progression-free&#xD;
      survival, in patients treated with this drug.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the median survival time of patients treated with this drug. II. Determine the&#xD;
      1-year survival rate and stable disease rate in patients treated with this drug.&#xD;
&#xD;
      III. Determine the response or stable disease duration in patients treated with this drug.&#xD;
&#xD;
      IV. Determine the toxicity of this drug in these patients. V. Determine the time to disease&#xD;
      progression in patients treated with this drug.&#xD;
&#xD;
      VI. Determine if changes in free VEGF Trap levels correlate with response or toxicity.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label study.&#xD;
&#xD;
      Patients are stratified according to prior bevacizumab treatment (yes vs no). Patients&#xD;
      receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients undergo blood collection at the&#xD;
      beginning of each course and at 60 days after completion of study treatment. Samples are&#xD;
      analyzed by immunoenzyme techniques to determine the pharmacokinetics of VEGF Trap.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 and 60 days and then every 3&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (Bevacizumab- naïve Group)</measure>
    <time_frame>4 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (Bevacizumab-treated Group)</measure>
    <time_frame>4 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Bevacizumab-naïve Group)</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier method will be used. (Bevacizumab- naïve Group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Prior Bevacizumab Treated Group)</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier method will be used (Bevacizumab-naïve Group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Stable Disease Rate</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response (Bevacizumab-naïve Group)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Bevacizumab-treated Group)</measure>
    <time_frame>6 months</time_frame>
    <description>Kaplan-Meier method will be used. (Bevacizumab-treated Group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Bevacizumab-treated Group)</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier method will be used (Bevacizumab-treated Group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response (Bevacizumab-treated Group)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>Given intravenously</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>vascular endothelial growth factor trap</other_name>
    <other_name>VEGF Trap</other_name>
    <other_name>Zaltrap</other_name>
    <other_name>ziv-aflibercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically/cytologically confirmed metastatic colorectal metastatic cancer&#xD;
&#xD;
          -  measurable disease (at least 1 lesion accurately measured in at least 1 dimension&#xD;
             (longest diameter) as&gt;20mm with conventional techniques or as &gt;10mm with spiral CT&#xD;
             scan&#xD;
&#xD;
          -  &gt;=4 weeks from major surgery&#xD;
&#xD;
          -  at least 1prior line of systemic therapy for metastatic disease. Prior treatment with&#xD;
             anti-epidermal growth factor receptor inhibitors is allowed. Last dose &gt;=4 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Two cohorts: 1) bevacizumab naïveand; 2) bevacizumab treated&#xD;
&#xD;
          -  May have received prior thymidylate synthetase inhibitor concurrently with radiation&#xD;
             as &quot;radiation sensitizer&quot;. Last dose &gt;=4 weeks prior to randomization&#xD;
&#xD;
          -  Prior radiation treatment &gt;=4 weeks prior to randomization&#xD;
&#xD;
          -  Age&gt;=18 years&#xD;
&#xD;
          -  Life expectancy &gt;=3 months&#xD;
&#xD;
          -  ECOG&lt;=2 (Karnofsky=60%)&#xD;
&#xD;
          -  leukocytes &gt;3.0x10^9/L&#xD;
&#xD;
          -  absolute neutrophil count &gt;1.5 x 10^9/L&#xD;
&#xD;
          -  platelets&gt;75x10^9/L&#xD;
&#xD;
          -  INR &lt;1.5 unless on warfarin&#xD;
&#xD;
          -  total bilirubin within 1.5xULN&#xD;
&#xD;
          -  AST/ALT≤2.5 X institution ULN&#xD;
&#xD;
          -  creatinine≤1.5xULN OR creatinine clearance &gt;60mL/min/1.73m2 for patients with&#xD;
             creatinine levels above1.5x institution limits&#xD;
&#xD;
          -  Urinalysis negative for protein OR 24h urine for protein &lt;500 mg&#xD;
&#xD;
          -  full-dose anticoagulants with PT INR &gt;1.5 eligible provided that: a) patient is&#xD;
             therapeutic on stable dose of warfarin or low molecular weight heparin; b) patients on&#xD;
             warfarin, the upper target for INR is &lt;=3; c) no active bleeding/pathological&#xD;
             condition carrying high bleeding risk&#xD;
&#xD;
          -  Eligibility of patients receiving medications known to affect activity/PK of VEGF Trap&#xD;
             will be determined by PI&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for at least 6 months after completion of&#xD;
             VEGF Trap therapy&#xD;
&#xD;
          -  Ability to understand/willingness to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior&#xD;
             to study entry&#xD;
&#xD;
          -  Other investigational agents concurrently&#xD;
&#xD;
          -  History of prior anti-angiogenic therapy other than bevacizumab&#xD;
&#xD;
          -  Evidence of CNS disease&#xD;
&#xD;
          -  Known hypersensitivity to Chinese hamster ovary cell products/other recombinant human&#xD;
             antibodies, and patients with a history of allergic reactions attributed to compounds&#xD;
             of similar chemical/biologic composition to other agents used in the study.&#xD;
&#xD;
          -  Serious/non-healing wound/ulcer/bone fracture&#xD;
&#xD;
          -  History of abdominal fistula/GI perforation/bowel obstruction/intraabdominal abscess&#xD;
             within 28 days of treatment&#xD;
&#xD;
          -  major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to Day 1 therapy&#xD;
&#xD;
          -  anticipation of need for major surgical procedures during study&#xD;
&#xD;
          -  core biopsy within 7 days prior to Day 1 therapy&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  PT INR &gt;1.5 unless the patient is on full-dose warfarin&#xD;
&#xD;
          -  Use of thrombolytic agents within 1 month of study initiation&#xD;
&#xD;
          -  Significant Proteinuria (&gt;500mg/24h): Urine protein should be screened by random&#xD;
             urinalysis for protein. If dipstick positive (&gt;1+), 24-hour urine protein should be&#xD;
             obtained and if &gt;500mg/24 h, patient will be excluded.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to ongoing or active&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             potential for PK interactions with VEGF Trap&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Moore</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 4, 2006</study_first_submitted>
  <study_first_submitted_qc>December 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <results_first_submitted>March 27, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2015</results_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VEGF Trap IV Arm I</title>
          <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given intravenously&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given orally&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="39" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given intravenously&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (Bevacizumab- naïve Group)</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Bevacizumab- naïve Group)</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (Bevacizumab-treated Group)</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Bevacizumab-treated Group)</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&#xD;
Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.9" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Bevacizumab-naïve Group)</title>
        <description>Kaplan-Meier method will be used. (Bevacizumab- naïve Group)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given intravenously&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Bevacizumab-naïve Group)</title>
          <description>Kaplan-Meier method will be used. (Bevacizumab- naïve Group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.6" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Prior Bevacizumab Treated Group)</title>
        <description>Kaplan-Meier method will be used (Bevacizumab-naïve Group)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Prior Bevacizumab Treated Group)</title>
          <description>Kaplan-Meier method will be used (Bevacizumab-naïve Group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="6.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Kaplan-Meier method will be used.</description>
        <time_frame>12 months</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given intravenously&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Kaplan-Meier method will be used.</description>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Stable Disease Rate</title>
        <time_frame>Up to 6 years</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Stable Disease Rate</title>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response (Bevacizumab-naïve Group)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response (Bevacizumab-naïve Group)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Bevacizumab-treated Group)</title>
        <description>Kaplan-Meier method will be used. (Bevacizumab-treated Group)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Bevacizumab-treated Group)</title>
          <description>Kaplan-Meier method will be used. (Bevacizumab-treated Group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="6.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Bevacizumab-treated Group)</title>
        <description>Kaplan-Meier method will be used (Bevacizumab-treated Group)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Bevacizumab-treated Group)</title>
          <description>Kaplan-Meier method will be used (Bevacizumab-treated Group)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="6.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response (Bevacizumab-treated Group)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
aflibercept: Given intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response (Bevacizumab-treated Group)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;&#xD;
Stable disease for atleast 16 weeks</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
ziv-aflibercept: Given orally&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Esophageal varices hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>DeathNOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Malcolm Moore</name_or_title>
      <organization>Princess Margaret Cancer Centre</organization>
      <phone>416-945-2263</phone>
      <email>malcolm.moore@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

